This is the first study to evaluate the feasibility of detecting somatic mutations of MYD88 and CXCR4 in the cfDNA derived from the PB plasma of patients with IgM monoclonal gammopathies. This evidence concerns the gene MYD88 and monoclonal gammopathy.